



Cannabinoids

Guest Editors:

Prof. Dr. Melanie Kelly

Department of Pharmacology,
Dalhousie University, Halifax, NS,
Canada

Prof. Dr. Christian Lehmann

Department of Anesthesiology,
Dalhousie University, Halifax, NS,
Canada

Deadline for manuscript
submissions:

closed (31 August 2019)

Message from the Guest Editors

Despite a 5000-year history of medicinal cannabis use, insights into the modern pharmacology of cannabis and cannabinoids only occurred over a more recent 50 year span, which was triggered when Gaoni and Mechoulam (1964) first identified delta9-tetrahydrocannabinol, the main psychoactive ingredient in cannabis. This was closely followed by the cloning of the cannabinoid type 1 receptor in the late 1980s and, shortly after, the cannabinoid type 2 receptor, both of which are targets for THC and cannabinoids. Identification of endogenous ligands (i.e., anandamide and 2-arachidonyl glycerol) that activate cannabinoid receptors laid the framework for an endogenous cannabinoid signaling system, which, together with receptors and enzymes for biosynthesis and degradation of endocannabinoids, was coined the “endocannabinoid system”—similar to other endogenous systems (e.g., the endorphin system). Currently, many synthetic agonists and antagonists, as well as naturally occurring “phytocannabinoids” that target the endocannabinoid system, have been investigated and found to exhibit significant potential as medicines in preclinical and clinical studies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical
Biology and Phytochemistry,
University of Münster,
Corrensstrasse 48, D-48149
Münster, Germany

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Reaxys](#), [CaPlus / SciFinder](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Chemistry, Multidisciplinary*) / CiteScore - Q1 (*Chemistry (miscellaneous)*)

Contact Us

Molecules Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/molecules
molecules@mdpi.com
[X@Molecules_MDPI](https://twitter.com/X@Molecules_MDPI)